Page 115 - 《中国药房》2023年17期
P. 115

5 d 和体重<50 kg 是该药引起低钾血症的独立危险因                      [12]  HOPE W W,GOODWIN J,FELTON T W,et al. Popula‐
          素。针对存在以上危险因素的患者,建议在开始使用两                                tion  pharmacokinetics  of  conventional  and  intermittent
          性霉素B脂质体治疗前将血清钾补充至正常水平,给药                                dosing of liposomal amphotericin B in adults:a first criti‐
          期间密切监测血清钾变化,以减少低钾血症的发生。                                 cal step for rational design of innovative regimens[J]. Anti‐
          参考文献                                                    microb Agents Chemother,2012,56(10):5303-5308.
                                                             [13]  LE T,LY V T,THU N T M,et al. Population pharmacody‐
          [ 1 ]  LIU M,CHEN M W,YANG Z W. Design of amphoteri‐
              cin B oral formulation for antifungal therapy[J]. Drug De‐  namics of amphotericin B deoxycholate for disseminated
                                                                  infection caused by Talaromyces marneffei[J]. Antimicrob
              liv,2017,24(1):1-9.
                                                                  Agents Chemother,2019,63(2):e01739-e01718.
          [ 2 ]  PAPPAS P G,KAUFFMAN C A,ANDES D R,et al. Exe-
              cutive summary:clinical practice guideline for the mana-   [14]  KARIMZADEH I,KHALILI H,FARSAEI S,et al. Role
                                                                  of diuretics and lipid formulations in the prevention of am‐
              gement  of  candidiasis:2016  update  by  the  Infectious
                                                                  photericin  B-induced  nephrotoxicity[J].  Eur  J  Clin  Phar‐
              Diseases Society of America[J]. Clin Infect Dis,2016,62
              (4):409-417.                                        macol,2013,69(7):1351-1368.
                                                             [15]  WADE R L,CHAUDHARI P,NATOLI J L,et al. Com‐
          [ 3 ]  SEIBEL N L,SHAD A T,BEKERSKY I,et al. Safety,tole-
              rability,and  pharmacokinetics  of  liposomal  amphotericin   parison of adverse events and hospital length of stay asso‐
                                                                  ciated with various amphotericin B formulations:sequen‐
              B  in  immunocompromised  pediatric  patients[J].  Antimi‐
                                                                  tial  conventional  amphotericin  b/lipid  versus  lipid-only
              crob Agents Chemother,2017,61(2):e01477-e01416.
          [ 4 ]  STEIMBACH L M,TONIN F S,VIRTUOSO S,et al. Ef‐    therapy for the treatment of invasive fungal infections in
                                                                  hospitalized patients[J]. P T,2013,38(5):278-287.
              ficacy and safety of amphotericin B lipid-based formula‐
                                                             [16]  OTA Y,OBATA Y,TAKAZONO T,et al. Association be‐
              tions:a systematic review and meta-analysis[J]. Mycoses,
                                                                  tween  potassium  supplementation  and  the  occurrence  of
              2017,60(3):146-154.
                                                                  acute kidney injury in patients with hypokalemia admini-
          [ 5 ]  STONE N R H,BICANIC T,SALIM R,et al. Liposomal
              amphotericin B (AmBisome(®)):a review of the phar‐  stered  liposomal  amphotericin  B:a  nationwide  observa‐
                                                                  tional study[J]. BMC Nephrol,2021,22(1):240.
              macokinetics,pharmacodynamics,clinical experience and
                                                             [17]  YAMAZAKI H,KONDO T,AOKI K,et al. Occurrence
              future directions[J]. Drugs,2016,76(4):485-500.
          [ 6 ]  PATEL G P,CRANK C W,LEIKIN J B. An evaluation of   and  improvement  of  renal  dysfunction  and  serum  potas‐
                                                                  sium abnormality during administration of liposomal am‐
              hepatotoxicity and nephrotoxicity of liposomal amphoteri‐
              cin B (L-AMB)[J]. J Med Toxicol,2011,7(1):12-15.    photericin  B  in  patients  with  hematological  disorders:a
                                                                  retrospective  analysis[J].  Diagn  Microbiol  Infect  Dis,
          [ 7 ]  OKADA  N,AZUMA  M,IMANISHI  M,et  al.  Potential
                                                                  2018,90(2):123-131.
              usefulness of early potassium supplementation for preven-
              ting severe hypokalemia induced by liposomal amphoteri‐  [18]  HAY R J. Liposomal amphotericin B,AmBisome[J]. J In‐
                                                                  fect,1994,28:35-43.
              cin  B  in  hematologic  patients:a  retrospective  study[J].
                                                             [19]  USAMI E,KIMURA M,KANEMATSU T,et al. Evalua‐
              Clin Ther,2018,40(2):252-260.
          [ 8 ]  朱彦,李志玲,孟琳懿,等 . 注射用两性霉素 B 脂质体致                    tion  of  hypokalemia  and  potassium  supplementation  du-
                                                                  ring  administration  of  liposomal-amphotericin  B[J].  Exp
              早产儿左心收缩功能不全 1 例[J]. 中国医院药学杂志,
              2017,37(4):402-403.                                 Ther Med,2014,7(4):941-946.
                                                             [20]  ABDEL-HAFEZ Y,SIAJ H,JANAJRI M,et al. Tolerabi-
          [ 9 ]  国家药典委员会. 中华人民共和国药典临床用药须知:中
                                                                  lity  and  epidemiology  of  nephrotoxicity  associated  with
              药卷[M]. 2005年版.北京:人民卫生出版社,2005:589.
          [10]  LEVEY A S,DE JONG P E,CORESH J,et al. The defini‐  conventional  amphotericin  B  therapy:a  retrospective
                                                                  study  in  tertiary  care  centers  in  Palestine[J].  BMC
              tion,classification,and  prognosis  of  chronic  kidney  di-
              sease:a KDIGO Controversies Conference report[J]. Kid‐  Nephrol,2022,23(1):132.
                                                             [21]  王学莉,伏添,王成立,等 . 两性霉素 B 治疗侵袭性肺部
              ney Int,2011,80(1):17-28.
                                                                  真菌感染的临床分析[J]. 中国真菌学杂志,2014,9(3):
          [11]  TASSET C,PREAT V,BERNARD A,et al. Comparison
              of nephrotoxicities of different polyoxyethyleneglycol for‐  163-166.
                                                                            (收稿日期:2023-02-28  修回日期:2023-08-17)
              mulations of amphotericin B in rats[J]. Antimicrob Agents
                                                                                                  (编辑:胡晓霖)
              Chemother,1992,36(7):1525-1531.











          中国药房  2023年第34卷第17期                                              China Pharmacy  2023 Vol. 34  No. 17    · 2153 ·
   110   111   112   113   114   115   116   117   118   119   120